Recent advances in alcoholic hepatitis.

alcohol-induced injury alcoholic liver disease

Journal

Frontline gastroenterology
ISSN: 2041-4137
Titre abrégé: Frontline Gastroenterol
Pays: England
ID NLM: 101528589

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 01 02 2019
revised: 07 04 2019
accepted: 29 04 2019
entrez: 6 3 2020
pubmed: 7 3 2020
medline: 7 3 2020
Statut: epublish

Résumé

Alcoholic hepatitis (AH) is an acute deterioration in liver function seen in the context of prolonged excessive alcohol consumption and is characterised by the rapid onset of jaundice. The diagnosis of AH has been controversial for many years: it is now accepted that there are clear clinical criteria which can be used to diagnose AH without the need for a liver biopsy. Corticosteroids remain the only treatment proven to be effective in reducing short-term mortality in severe AH; abstinence from alcohol is the most important factor in determining long-term survival. It is recommended a trial of corticosteroid therapy is considered only in those patients with high baseline 'static' scores (Glasgow Alcoholic Hepatitis score and model for end-stage liver disease). Response to corticosteroid therapy should be assessed using a 'dynamic' score such as the Lille score at day 7, with corticosteroids continuing only in patients with a favourable score. Infection and acute kidney injury are associated with poorer outcomes in AH. Early screening for and treatment of infection is recommended with antibiotic therapy overlapping with any subsequent corticosteroid treatment. A biomarker which predicts benefit from corticosteroids at baseline would avoid a trial of therapy to determine response. More efficacious therapeutic options for AH patients are required with N-acetylcysteine, granulocyte colony stimulating factor, faecal microbiota transplantation and routine antibiotics showing promise, but adequate controlled trials are needed to confirm efficacy. Liver transplant has an emerging role for some patients with severe AH not responding to corticosteroids and is likely to become more acceptable with improved methods of patient selection.

Identifiants

pubmed: 32133112
doi: 10.1136/flgastro-2018-101104
pii: flgastro-2018-101104
pmc: PMC7043083
doi:

Types de publication

Journal Article

Langues

eng

Pagination

133-139

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: Neither JV or EHF have received any funding or have any conflicts of interest with regards to this manuscript.

Références

Am J Gastroenterol. 2014 Sep;109(9):1417-23
pubmed: 24935272
Clin Gastroenterol Hepatol. 2012 Jan;10(1):65-71.e3
pubmed: 21946124
Virchows Arch. 2018 Apr;472(4):667-675
pubmed: 29516163
Am J Gastroenterol. 2018 Feb;113(2):175-194
pubmed: 29336434
Gastroenterology. 2008 Dec;135(6):1953-60
pubmed: 18848937
Gastroenterology. 2015 Oct;149(4):958-70.e12
pubmed: 26091937
J Hepatol. 2018 Mar;68(3):511-518
pubmed: 29175535
J Hepatol. 2015 Apr;62(4):816-21
pubmed: 25450199
Gastroenterology. 2018 Aug;155(2):458-468.e8
pubmed: 29738698
Hepatology. 2017 Nov;66(5):1464-1473
pubmed: 28459138
Gastroenterology. 2012 Mar;142(3):505-512.e1
pubmed: 22119930
J Clin Gastroenterol. 2019 Jul;53(6):e243-e252
pubmed: 29369844
N Engl J Med. 2015 Apr 23;372(17):1619-28
pubmed: 25901427
N Engl J Med. 2011 Nov 10;365(19):1790-800
pubmed: 22070476
Gastroenterology. 2016 Apr;150(4):903-10.e8
pubmed: 26764182
N Engl J Med. 2011 Nov 10;365(19):1781-9
pubmed: 22070475
J Hepatol. 2018 Aug;69(2):318-324
pubmed: 29524528
Gastroenterology. 2018 Aug;155(2):422-430.e1
pubmed: 29655837
J Hepatol. 2018 Jul;69(1):154-181
pubmed: 29628280
Gastroenterology. 2000 Dec;119(6):1637-48
pubmed: 11113085
Am J Gastroenterol. 2019 Jan;114(1):175-176
pubmed: 29887598
Hepatology. 2019 Apr;69(4):1477-1487
pubmed: 30561766
Am J Gastroenterol. 2017 Feb;112(2):306-315
pubmed: 27922027
Gastroenterology. 2015 Aug;149(2):398-406.e8; quiz e16-7
pubmed: 25935634
Gastroenterology. 2009 Aug;137(2):541-8
pubmed: 19445945
Gastroenterology. 2017 Apr;152(5):1068-1077.e4
pubmed: 28043903
Aliment Pharmacol Ther. 2018 Apr;47(8):1151-1161
pubmed: 29460445
Liver Transpl. 2018 Mar;24(3):380-393
pubmed: 29171941
J Hepatol. 2008 Mar;48(3):465-70
pubmed: 18164508
Hepatology. 2007 Jun;45(6):1348-54
pubmed: 17518367
Liver Transpl. 2018 Dec;24(12):1655-1664
pubmed: 30153377
Liver Int. 2015 Aug;35(8):1974-82
pubmed: 25611961
Hepatology. 2004 May;39(5):1390-7
pubmed: 15122768
Gastroenterology. 2016 Apr;150(4):785-90
pubmed: 26921783
Liver Int. 2008 Dec;28(10):1344-51
pubmed: 18482269
Indian J Gastroenterol. 2018 May;37(3):215-225
pubmed: 29931479

Auteurs

Jennifer Veryan (J)

Liver Unit, Glasgow Royal Infirmary, Glasgow, Glasgow, UK.

E H Forrest (EH)

Liver Unit, Glasgow Royal Infirmary, Glasgow, Glasgow, UK.
College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, Glasgow, UK.

Classifications MeSH